SGLT2 Inhibitor Drugs Can Now Include Reducing Heart Disease on Their Labels In Europe

Diabetes Drug Infection Lawsuit News

Diabetic patients should continue to be monitored for life-threatening side effects of SGLT2 drugs including Fournier's Gangrene

Thursday, August 29, 2019 - Sodium-glucose transporter drugs work to re-route sugar from the blood and out directly through the urine, lowering blood glucose levels without relying on insulin. According to the National Institute of Health (NIH), "SGLT2 inhibitors function through a novel mechanism of reducing renal tubular glucose re-absorption, producing a reduction in blood glucose without stimulating insulin release." The drugs are popular among newly diagnosed diabetic patients that are unwilling to take insulin injections. In addition to lowering blood glucose levels, SGLT2 blocker drugs are proving to help control cardiovascular disease (CVD). The drugs are so effective in helping those with CVD, the European Health Commission recently approved Farixa to include the heart-related benefits on their labeling. Drug companies have been eager to get the added benefits on their drug's label to increase their potential customer base and sell more drugs. The NIH writes that optimism should be tempered as longer-term studies of the drugs newfound efficacy are needed. Other benefits of SGLT2 drugs, in addition to the cardiovascular benefits, are that they aid in controlling high blood pressure and aid in losing weight. Diabetes drug infection lawsuit claims give persons and families harmed by necrotizing fasciitis from diabetes drugs the means to seek compensation for damage caused this severe side effect of certain diabetes drugs.

Although diabetic patients on SGLT2 inhibitor drugs may be relieved that they now have one less adverse side effect to worry about, they should also be concerned about another potential life-threatening disease that has been recently linked to sodium-glucose blocker drugs. Diabetes sufferers on (SGLT2) medication to treat their type-2 need to be worried about Fournier's Gangrene, a form of the flesh-eating disease that consumes the perineum region of the genitals between the anus and the scrotum. SGLT2 drugs include canagliflozin (Invokana), canagliflozin/metformin (Invokamet), and dapagliflozin (Farxiga), the most popular US brands of the drug. The US Food and Drug Administration has issued a security alert warning diabetes patients and physicians to closely monitor their condition for signs that they may have developed Fournier's Gangrene. The FDA Fournier's Gangrene warning is especially pertinent for those with elderly loved ones that have been placed in the care of a nursing home. Many nursing home patients are taking SGLT2 drugs and can be oblivious to the connection to contracting the flesh-eating disease. Nursing homes are notorious for ignoring their "client's" special medical needs and there have been reports of flesh-eating disease of the genitals occurring.

Diabetic nursing home patients should be watched for the early signs of Fournier's Gangrene that include pain in the testicle of the perineum, swelling, redness. Fournier's Gangrene may also be revealed by a crackling sound when the area in question is pressed. More advanced stages of Fournier's Gangrene include a blackening of the skin and a foul order created by tissue death. Fournier's Gangrene patients have around a 50% chance of survival depending on when the condition is diagnosed and treated. Diabetic patients with any of the above symptoms should be rushed to the hospital for treatment with antibiotics and the removal of dead tissue.

More Recent Diabetes Drug Infection Lawsuit News:

Lawyers for Fournier's Gangrene

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.